Management ChangeJul 16, 2026, 08:16 AM
enGene Appoints Michael Heffernan as Chairman; Dr. Glickman Resigns
AI Summary
enGene Therapeutics announced a change in its Board leadership, with Dr. Richard Glickman resigning as director and chairman, effective July 15, 2026. His departure was amicable and not due to any disagreements. Michael Heffernan, who joined the Board in July 2025 and has over 30 years of biopharmaceutical experience, has been appointed as the new Chairman. These changes are intended to strategically position the company for upcoming regulatory and commercial milestones, including a planned pre-BLA meeting and BLA submission for detalimogene in the second half of 2026, with potential FDA approval in 2027.
Key Highlights
- Dr. Richard Glickman resigned as director and chairman of enGene's Board, effective July 15, 2026.
- His resignation was not due to any disagreement with the Company.
- Michael Heffernan, a current Board member since July 2025, was appointed as the new Chairman.
- Heffernan brings over 30 years of biopharmaceutical industry experience, including founding Collegium Pharmaceutical.
- The Board changes are to support planned regulatory and commercial milestones for detalimogene.
- A pre-Biologics License Application (BLA) meeting with the FDA is planned for 2H 2026.
- Initiation of BLA submission for detalimogene is planned for 2H 2026.
- Potential FDA approval of detalimogene is anticipated in 2027.
Price Impact
More from ENGN